Ramez Rizk, PharmD Candidate

AbbVie Inc.

Poster(s):

• (190) Budget impact analysis of generic mirabegron in Medicare Part D: translating savings into access
  Wednesday, October 29, 2025

• (293) Real-World Clinical Outcomes and Healthcare Resource Utilization with Covalent BTK Inhibitors in CLL/SLL (2020–2025): A Systematic Review
  Wednesday, October 29, 2025